Marlene Debel

EVP & Chief Risk Officer Marlene Debel sold 21,312 shares of MET at $81.59; retains 154,380 shares post-sale.

Marlene Debel, EVP & Chief Risk Officer, sold 21,312 shares at $81.59 on 2026-06-01, reducing her non-derivative holdings by 12.1% to 154,380 shares. The current price of $80.98 is -5.0% from the 52-week high of $85.29, and the stock is up 11.0% over the past 90 days. Her prior sell at this ticker on 2024-12-13 posted a 90-day return of -6.2%, consistent with her cross-ticker track record of 1 prior sells averaging -6.2% over 90 days and a 100.00% well-timed rate. The transaction removes $1,738,822.64 worth of stock from her directly-held portfolio while she retains a substantial position in the company where she serves as Chief Risk Officer.

EVP & Chief Risk Officer DEBEL MARLENE sells 22,810 shares of MET at $82.88; retains 108,507 shares post-sale.

DEBEL MARLENE, serving as EVP & Chief Risk Officer, sold 22,810 shares at $82.88 on 2024-12-13, reducing her holding by 17.4% to 108,507 shares and generating $1,890,577.20. The sale occurred near the top of the 52-week range ($65.22–$88.25), with MET currently trading at $81.25, 7.9% below its 52-week high. At $56.3B market cap and a P/E of 14.96, MetLife is a mature financial services company; revenue declined 4.3% year-over-year in the latest reporting period. The executive retained substantial holdings post-transaction, indicating continued material ownership in the firm.